Company: IXHL
Filing Date: 2025-04-17
Form Type: PRER14A
Source: 0001213900-25-033013
Chunk: 21

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-17
Form: PRER14A
Chunk 21
---
 Price and after giving effect to the zero exercise price provision) in the event of an adjustment upon the Adjustment  
 Date (i.e. the close of trading on the 11th trading day after the Release Date, which is the later of the date the Warrant                
 Shares may be resold pursuant to an effective registration statement or Rule 144 and the date of the Warrant Stockholder Approval), as    
 defined and described below, without regard to any limitations upon exercise of the Series A Warrants relating to the Warrant Stockholder 
 Approval and/or the provisions prohibiting adjustments in such Series A Warrants above the Floor Price of $0.216;                         |

<div align='center'>11</div>

| (b) | to consent to any adjustment to the exercise price (as low as the Floor Price of $0.216 per share) and/or number of shares of common       
 stock underlying the Series A Warrants (from 11,574,090 to up to 115,740,900, assuming full adjustment of the exercise price to the Floor  
 Price and before giving effect to the zero exercise price provision and up to 347,222,700 assuming full adjustment of the exercise         
 price to the Floor Price and after giving effect to the zero exercise price provision) in the event of a Share Combination Event           
 (i.e. any share split, reverse share split, share dividend, share combination recapitalization or other similar transaction involving      
 the shares of our common stock), as defined and described below, without regard to any limitations upon exercise of the Series A Warrants  
 relating to the Warrant Stockholder Approval and/or the provisions prohibiting adjustments in such Series A Warrants above the Floor Price 
 of $0.216;                                                                                                                                 |

| (c) | to consent to any adjustment to the exercise price of the Series A Warrants in the event of a voluntary adjustment described below; |

| (d) | to consent, without regard to any limitations upon exercise of the Series                                                                     
 A Warrants relating to the Warrant Stockholder Approval and/or the provisions prohibiting adjustments in such Series A Warrants above         
 the Floor Price of $0.216, to the zero exercise price provision of the Series A Warrant (which is referred to in the text of the Series       
 A Warrants as an “alternative cashless exercise”) whereby, following the Warrant Stockholder Approval (even if a registration                 
 statement registering the issuance or resale of shares of common stock underlying the Series A Warrant is effective), the holder of a